ALNY
Alnylam Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-47/100
Last price
225.00
▲ 5.11 (2.32%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
222.44
Prev close
219.89
Day high
229.12
Day low
217.18
Volume
1.36M
Market cap
$29.97B
P/E (TTM)
37.08
52W range
197.81 – 495.55
Day trading desk
Gap from prior close
+1.16%
Prior close 219.89
VWAP
224.77
+0.10% from price
Relative volume
1.28×
Normal
Session range
5.50%
217.18 – 229.12
Position in range
65%
Mid range
ATR (14D)
9.53
4.24% of price
Prior day high
222.08
PDH
Prior day low
215.46
PDL
Bid / ask spread
—
Quote not published
Session volume
2.35M
Avg 1.84M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-11.86%
-13.8%
1M
-15.85%
-17.0%
3M
-30.78%
-35.3%
6M
-29.91%
-48.1%
YTD
-43.68%
-57.9%
1Y
-50.93%
-67.3%
3Y
+26.45%
-55.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on ALNY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+17.56K
Net buying
Buy transactions
12
21.39K shares
Sell transactions
1
3.83K shares
Net transactions
+13
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
246.21K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 18, 26 | GREENSTREET YVONNE L Chief Executive Officer |
STOCK | 107 | $0 | Direct |
| Jun 1, 26 | PYOTT DAVID E I Director |
SELL | 3.83K | $1.15M | Direct |
| Jun 1, 26 | PYOTT DAVID E I Director |
— | 3.83K | — | Direct |
| May 20, 26 | REITAN COLLEEN F. Director |
STOCK | 671 | $0 | Direct |
| May 20, 26 | SIGAL CHARLES ELLIOTT Director |
STOCK | 671 | $0 | Direct |
| May 20, 26 | PYOTT DAVID E I Director |
STOCK | 671 | $0 | Direct |
| May 20, 26 | BRANDICOURT OLIVIER Director |
STOCK | 671 | $0 | Direct |
| May 20, 26 | ARBUCKLE STUART A Director |
STOCK | 671 | $0 | Direct |
| May 20, 26 | KELLOGG PETER N Director |
STOCK | 671 | $0 | Direct |
| May 20, 26 | HAMBURG MARGARET A Director |
STOCK | 671 | $0 | Direct |
| May 20, 26 | AUSIELLO DENNIS A Director |
STOCK | 671 | $0 | Direct |
| May 20, 26 | SCHULMAN AMY W. Director |
STOCK | 838 | $0 | Direct |
| May 13, 26 | SCHULMAN AMY W. Director |
CONVERSION | 11.25K | $789.75K | Direct |
| Apr 6, 26 | MCLAUGHLIN MELISSA Officer |
SELL | 3.91K | $1.27M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BONNEY MICHAEL W |
Director | 20.80K | Sale |
FITZGERALD KEVIN JOSEPH |
Officer | 21.11K | Sale |
GARG PUSHKAL |
Officer | 19.37K | Sale |
GREENSTREET YVONNE L |
Chief Executive Officer | 96.21K | Stock Award(Grant) |
POULTON JEFFREY V |
Chief Financial Officer | 61.86K | Sale |
PYOTT DAVID E I |
Director | 29.48K | Sale |
SCHULMAN AMY W. |
Director | 24.05K | Stock Award(Grant) |
SHARP PHILLIP A |
Director | 266.90K | Sale |
SUPRAN BRYAN |
Officer | 14.56K | Stock Award(Grant) |
TANGULER TOLGA |
Officer | 34.30K | Sale |
Fundamentals
Market cap$29.97B
Enterprise value$29.64B
Revenue (TTM)$4.80B
Gross profit$3.83B
EBITDA$1.05B
Net income$774.71M
EPS (TTM)$6.04
Free cash flow$271.54M
Total cash$3.31B
Total debt$2.99B
Book value / share$10.13
Shares outstanding133.81M
Float133.24M
Short % of float7.16%
Dividend yield0.00%
Beta (5Y)0.27
Valuation & profitability ratios
Trailing P/E37.08
Forward P/E17.96
PEG ratio0.28
Price / sales—
Price / book22.12
EV / revenue6.17
EV / EBITDA28.11
Gross margin79.65%
Operating margin17.93%
Profit margin16.13%
Return on equity96.56%
Return on assets12.34%
Debt / equity220.62
Current ratio3.06
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $3.71B | $2.25B | $1.83B | $1.04B | +65.2% |
| Operating revenue | $3.71B | $2.25B | $1.83B | $1.04B | +65.2% |
| Cost of revenue | $681.87M | $323.37M | $310.41M | $168.82M | +110.9% |
| Gross profit | $3.03B | $1.92B | $1.52B | $868.60M | +57.5% |
| Research & development | $1.32B | $1.13B | $1.00B | $883.01M | +17.2% |
| Selling, general & admin | $1.21B | $975.53M | $795.65M | $770.66M | +24.1% |
| Total operating expense | $2.53B | $2.10B | $1.80B | $1.65B | +20.4% |
| Operating income | $501.58M | -$176.88M | -$282.18M | -$785.07M | +383.6% |
| Net interest income | -$141.16M | -$19.87M | -$25.66M | -$131.16M | -610.5% |
| Pre-tax income | $323.15M | -$377.38M | -$433.52M | -$1.13B | +185.6% |
| Tax provision | $9.40M | -$99.22M | $6.72M | $4.16M | +109.5% |
| Net income | $313.75M | -$278.16M | -$440.24M | -$1.13B | +212.8% |
| Net income to common | $313.75M | -$278.16M | -$440.24M | -$1.13B | +212.8% |
| Basic EPS | 2.39 | -2.18 | -3.52 | -9.30 | +209.6% |
| Diluted EPS | 2.33 | -2.18 | -3.52 | -9.30 | +206.9% |
| EBIT | $575.78M | -$235.52M | -$312.30M | -$971.02M | +344.5% |
| EBITDA | $631.44M | -$178.85M | -$258.24M | -$926.56M | +453.1% |
| Basic shares | 131.00M | 127.65M | 124.91M | 121.69M | +2.6% |
| Diluted shares | 134.68M | 127.65M | 124.91M | 121.69M | +5.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.66B | $966.43M | $812.69M | $866.39M | +71.5% |
| Cash & short-term investments | $2.91B | $2.69B | $2.44B | $2.19B | +7.9% |
| Accounts receivable | $777.57M | $405.31M | $327.79M | $237.96M | +91.8% |
| Inventory | $82.72M | $78.51M | $89.15M | $128.96M | +5.4% |
| Total current assets | $4.05B | $3.30B | $2.98B | $2.69B | +22.9% |
| Property, plant & equipment | $708.06M | $693.93M | $725.79M | $738.63M | +2.0% |
| Total assets | $4.97B | $4.24B | $3.83B | $3.55B | +17.1% |
| Total current liabilities | $1.47B | $1.19B | $967.79M | $767.91M | +23.6% |
| Long-term debt | $1.01B | $1.02B | $1.02B | $1.02B | -1.6% |
| Total debt | $1.28B | $1.30B | $1.31B | $1.32B | -1.4% |
| Total liabilities | $4.18B | $4.17B | $4.05B | $3.70B | +0.1% |
| Retained earnings | -$6.70B | -$7.29B | -$7.01B | -$6.57B | +8.0% |
| Shareholder equity | $789.18M | $67.09M | -$220.64M | -$158.22M | +1,076.3% |
| Working capital | $2.58B | $2.11B | $2.01B | $1.92B | +22.5% |
| Net tangible assets | $789.18M | $67.09M | -$220.64M | -$158.22M | +1,076.3% |
| Shares issued | 132.38M | 129.29M | 125.79M | 123.92M | +2.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $313.75M | -$278.16M | -$440.24M | -$1.13B | +212.8% |
| Depreciation & amortisation | $55.66M | $56.67M | $54.05M | $44.47M | -1.8% |
| Stock-based compensation | $348.24M | $272.08M | $221.68M | $230.65M | +28.0% |
| Change in working capital | -$444.78M | -$214.08M | $57.26M | $7.62M | -107.8% |
| Operating cash flow | $524.08M | -$8.31M | $104.16M | -$541.27M | +6,405.1% |
| Capital expenditure | -$58.70M | -$34.28M | -$62.21M | -$72.06M | -71.2% |
| Investing cash flow | $436.33M | -$116.84M | -$336.35M | $169.35M | +473.4% |
| Financing cash flow | -$305.19M | $294.16M | $172.13M | $425.75M | -203.8% |
| Free cash flow | $465.38M | -$42.59M | $41.95M | -$613.33M | +1,192.7% |
| End cash position | $1.66B | $968.65M | $814.88M | $868.56M | +71.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.29B | $1.17B | $1.10B | $1.25B | $773.69M | +10.6% |
| Operating revenue | $1.29B | $1.17B | $1.10B | $1.25B | $773.69M | +10.6% |
| Cost of revenue | $298.45M | $211.12M | $267.72M | $200.15M | $142.95M | +41.4% |
| Gross profit | $992.50M | $956.05M | $829.31M | $1.05B | $630.74M | +3.8% |
| Research & development | $413.13M | $364.87M | $372.22M | $358.81M | $323.62M | +13.2% |
| Selling, general & admin | $347.92M | $322.55M | $325.37M | $322.08M | $323.31M | +7.9% |
| Total operating expense | $761.06M | $687.42M | $697.59M | $680.89M | $646.93M | +10.7% |
| Operating income | $231.44M | $268.64M | $131.72M | $367.98M | -$16.20M | -13.8% |
| Net interest income | -$53.91M | -$42.69M | -$102.71M | -$15.72M | -$33.97M | -26.3% |
| Pre-tax income | $177.81M | $221.65M | $161.14M | $238.97M | -$41.31M | -19.8% |
| Tax provision | $13.31M | $15.66M | -$25.28M | -$12.12M | $30.92M | -15.0% |
| Net income | $164.49M | $205.99M | $186.42M | $251.08M | -$72.23M | -20.1% |
| Net income to common | $164.49M | $205.99M | $186.42M | $251.08M | -$72.23M | -20.1% |
| Basic EPS | 1.23 | 1.55 | 0.84 | 1.91 | -0.55 | -20.6% |
| Diluted EPS | 1.21 | 1.51 | 0.82 | 1.84 | -0.55 | -19.9% |
| EBIT | $259.86M | $290.94M | $290.47M | $283.37M | $20.15M | -10.7% |
| EBITDA | $273.76M | $304.49M | $303.98M | $297.17M | $34.09M | -10.1% |
| Basic shares | 133.61M | 132.89M | 132.23M | 131.45M | 130.63M | +0.5% |
| Diluted shares | 138.28M | 138.23M | 136.28M | 137.35M | 130.63M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | -0.1% |
| Cash & short-term investments | $3.31B | $3.01B | $2.91B | $2.72B | $2.86B | +9.9% |
| Accounts receivable | $912.74M | $883.96M | $777.57M | $964.77M | $567.11M | +3.3% |
| Inventory | $97.11M | $84.03M | $82.72M | $75.38M | $71.69M | +15.6% |
| Total current assets | $4.62B | $4.22B | $4.05B | $3.95B | $3.64B | +9.5% |
| Property, plant & equipment | $737.50M | $707.56M | $708.06M | $693.14M | $692.19M | +4.2% |
| Total assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | +8.4% |
| Total current liabilities | $1.51B | $1.35B | $1.47B | $1.56B | $1.30B | +12.1% |
| Long-term debt | $1.01B | $1.01B | $1.01B | $1.04B | $1.03B | +0.2% |
| Total debt | $1.27B | $1.27B | $1.28B | $1.31B | $1.30B | -0.4% |
| Total liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | +3.7% |
| Retained earnings | -$6.33B | -$6.50B | -$6.70B | -$7.16B | -$7.41B | +2.5% |
| Shareholder equity | $1.35B | $1.08B | $789.18M | $233.89M | $250.59M | +25.9% |
| Working capital | $3.11B | $2.87B | $2.58B | $2.40B | $2.34B | +8.3% |
| Net tangible assets | $1.35B | $1.08B | $789.18M | $233.89M | $250.59M | +25.9% |
| Shares issued | 133.73M | 133.44M | 132.38M | 131.79M | 130.98M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $164.49M | $205.99M | $186.42M | $217.81M | -$72.23M | -20.1% |
| Depreciation & amortisation | $13.90M | $13.55M | $13.51M | $13.80M | $13.94M | +2.6% |
| Stock-based compensation | $86.63M | $70.15M | $71.63M | $108.21M | $111.68M | +23.5% |
| Change in working capital | -$28.27M | -$297.73M | -$73.15M | -$178.74M | $26.15M | +90.5% |
| Operating cash flow | $326.72M | $70.50M | $163.56M | $351.03M | $129.81M | +363.4% |
| Capital expenditure | -$34.68M | -$21.83M | -$23.29M | -$12.14M | -$14.29M | -58.8% |
| Investing cash flow | -$363.46M | -$25.54M | -$37.17M | $501.11M | -$141.38M | -1,323.0% |
| Financing cash flow | $36.24M | $15.71M | $45.32M | -$474.27M | $77.68M | +130.6% |
| Free cash flow | $292.04M | $48.67M | $140.26M | $338.89M | $115.51M | +500.0% |
| End cash position | $1.71B | $1.71B | $1.66B | $1.49B | $1.12B | -0.2% |
Options analytics
Put / call volume
0.16
Call-heavy session
Put / call open interest
0.66
Positioning, not flow
Max pain
230.00
+2.7% from spot
ATM implied vol
50.6%
Nearest strike to spot
Skew (10% OTM)
+5.0%
Puts bid over calls
Call volume
385
Contracts, this expiry
Put volume
62
Contracts, this expiry
Heaviest call OI
250.00
1.20K contracts
Heaviest put OI
220.00
625 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.14 | 1.84 | -14.2% |
| Mar 2026 | 1.47 | 1.99 | +35.3% |
| Dec 2025 | 1.50 | 1.25 | -16.5% |
| Sep 2025 | 1.75 | 2.90 | +66.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.31 | 14 | $1.44B | +15.1% |
| Next quarter | 2.71 | 14 | $1.57B | +42.8% |
| Current year | 8.83 | 14 | $5.48B | +47.6% |
| Next year | 12.42 | 14 | $6.94B | +26.7% |
Analyst targets & ownership
Mean target$371.12
High target$536.00
Low target$256.00
Implied upside64.94%
Analyst count26
ConsensusBUY
Strong buy / Buy6 / 16
Hold7
Sell / Strong sell0 / 0
Held by insiders0.18%
Held by institutions101.82%
Institutions holding1.19K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
240.30
-6.37% from price
SMA 20
243.29
-7.95% from price
SMA 50
239.36
-6.44% from price
SMA 100
265.49
-15.25% from price
SMA 200
301.18
-25.65% from price
EMA 12
236.79
-4.98% from price
EMA 26
241.75
-6.93% from price
EMA 50
247.98
-9.27% from price
RSI (14)
37.8
Neutral
MACD (12,26,9)
-4.96
Hist -3.34
ATR (14)
9.53
4.26% of price
Realised vol 30D
45.4%
Annualised
Bollinger upper
265.86
20, 2σ
Bollinger lower
220.72
20, 2σ
50 / 200 cross
Death
239.36 vs 301.18
Trend bias
Below 200
-25.65%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.40
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
45.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-58.2%
Peak to trough
Max drawdown 5Y
-58.2%
Peak to trough
ATR 14
9.53
4.26% of price
Beta (reported)
0.27
5Y monthly, from filing
Short interest
Shares short
7.19M
Prior 4.77M
Change vs prior
+50.8%
Shorts adding
% of float
7.16%
Normal
% of shares out
5.38%
Against total outstanding
Days to cover
4.2
Liquid
Float
133.24M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Sep 21, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 8, 26 | Jefferies | MAINTAINED | Hold | Hold |
| Sep 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 19, 26 | BMO Capital | INITIATED | Outperform | Outperform |
| Aug 14, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 4, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 3, 26 | Raymond James | UPGRADE | Outperform | Strong Buy |
| Aug 3, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 3, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 31, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-04-30
Proxy Statements
DEF 14A · 2026-04-06
Corporate Changes & Voting Matters
8-K · 2026-03-04
Offering Registrations
S-8 · 2026-02-12
Corporate Changes & Voting Matters
8-K · 2026-01-12
Corporate Changes & Voting Matters
8-K · 2025-12-11
Headlines
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
Zacks · 14h ago
3 Great Healthcare Stocks To Own In October 2026
Simply Wall St. · 5d ago
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Business Wire · 8d ago
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Zacks · 9d ago
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Motley Fool · 9d ago
RNAi drug specialist ADARx raises $446M IPO
BioPharma Dive · 12d ago
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Trefis · 14d ago
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Zacks · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.